• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Translational Oncology >Predicting Treatment Response of Breast Cancer to Neoadjuvant Chemotherapy Using Ultrasound-Guided Diffuse Optical Tomography
【24h】

Predicting Treatment Response of Breast Cancer to Neoadjuvant Chemotherapy Using Ultrasound-Guided Diffuse Optical Tomography

机译：使用超声引导的漫射光学层析成像技术预测乳腺癌对新辅助化疗的治疗反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To prospectively investigate ultrasound-guided diffuse optical tomography (US-guided DOT) in predicting breast cancer response to neoadjuvant chemotherapy (NAC). MATERIALS AND METHODS: Eighty-eight breast cancer patients, with a total of 93 lesions, were included in our study. Pre– and post–last chemotherapy, size and total hemoglobin concentration (THC) of each lesion were measured by conventional US and US-guided DOT 1 day before biopsy (time point t0, THC THC0, SIZE S0) and 1 to 2 days before surgery (time point tL, THCL, SL). The relative changes in THC and SIZE of lesions after the first and last NAC cycles were considered as the variables ΔTHC and ΔSIZE. Receiver operating characteristic curve was performed to calculate ΔTHC and ΔSIZE cutoff values to evaluate pathologic response of 93 breast cancers to NAC, which were then prospectively used to predicate response of 61 breast cancers to NAC. RESULTS: The cutoff values of ΔTHC and ΔSIZE for evaluation of breast cancers NAC treatment response were 23.9% and 42.6%. At ΔTHC 23.9%, the predicted treatment response in 61 breast lesions for the time points t1 to t3 was calculated by area under the curve (AUC), which were AUC 1 0.534 ( P =.6668), AUC 2 0.604 ( P =.1893), and AUC 3 0.674( P =. 0.027), respectively; for ΔSIZE 42.6%, at time points t1 to t3, AUC 1 0.505 ( P =.9121), AUC 2 0.645 ( P =.0115), and AUC 3 0.719 ( P =.0018). CONCLUSION: US-guided DOT ΔTHC 23.9% and US ΔSIZE 42.6% can be used for the response evaluation and earlier prediction of the pathological response after three rounds of chemotherapy.
机译：目的：前瞻性研究超声引导的弥散光学断层扫描（美国指导的DOT），以预测乳腺癌对新辅助化疗（NAC）的反应。材料与方法：88例乳腺癌患者共93个病灶，被纳入我们的研究。最后一次化疗前后，每个病灶的大小和总血红蛋白浓度（THC）在活检前1天（时间点t0，THC THC0，SIZE S0）和之前1至2天通过常规US和US指导的DOT进行测量手术（时间点tL，THCL，SL）。在第一个和最后一个NAC周期后，病变的THC和SIZE的相对变化被视为变量ΔTHC和ΔSIZE。进行受试者工作特征曲线以计算ΔTHC和ΔSIZE临界值，以评估93种乳腺癌对NAC的病理反应，然后将其预期用于预测61种乳腺癌对NAC的反应。结果：用于评估乳腺癌NAC治疗反应的ΔTHC和ΔSIZE的临界值为23.9％和42.6％。在ΔTHC23.9％时，通过曲线下面积（AUC）计算61个乳腺病变在t1至t3时间点的预期治疗反应，即AUC 1 0.534（P = .6668），AUC 2 0.604（P =。 1893）和AUC 3 0.674（P = .0.027）;对于ΔSIZE42.6％，在时间点t1至t3处，AUC 1 0.505（P = .9121），AUC 2 0.645（P = .0115）和AUC 3 0.719（P = .0018）。结论：美国指导的DOTΔTHC23.9％和USΔSIZE42.6％可用于三轮化疗后的反应评估和更早的病理反应预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号